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AbstrAct
Background The European Society for Medical Oncology 
(ESMO) has developed the ESMO Magnitude of Clinical 
Benefit Scale (ESMO-MCBS), a tool to assess the 
magnitude of clinical benefit from new cancer therapies. 
Grading is guided by a dual rule comparing the relative 
benefit (RB) and the absolute benefit (AB) achieved by 
the therapy to prespecified threshold values. The ESMO-
MCBS v1.0 dual rule evaluates the RB of an experimental 
treatment based on the lower limit of the 95%CI (LL95%CI) 
for the hazard ratio (HR) along with an AB threshold. This 
dual rule addresses two goals: inclusiveness: not unfairly 
penalising experimental treatments from trials designed 
with adequate power targeting clinically meaningful 
relative benefit; and discernment: penalising trials 
designed to detect a small inconsequential benefit.
Methods Based on 50 000 simulations of plausible trial 
scenarios, the sensitivity and specificity of the LL95%CI 
rule and the ESMO-MCBS dual rule, the robustness of their 
characteristics for reasonable power and range of targeted 
and true HRs, are examined. The per cent acceptance of 
maximal preliminary grade is compared with other dual 
rules based on point estimate (PE) thresholds for RB.
Results For particularly small or particularly large studies, 
the observed benefit needs to be relatively big for the 
ESMO-MCBS dual rule to be satisfied and the maximal 
grade awarded. Compared with approaches that evaluate 
RB using the PE thresholds, simulations demonstrate that 
the MCBS approach better exhibits the desired behaviour 
achieving the goals of both inclusiveness and discernment.
Conclusions RB assessment using the LL95%CI for 
HR rather than a PE threshold has two advantages: it 
diminishes the probability of excluding big benefit positive 
studies from achieving due credit and, when combined 
with the AB assessment, it increases the probability of 
downgrading a trial with a statistically significant but 
clinically insignificant observed benefit.
IntRoduCtIon
The European Society for Medical Oncology 
(ESMO) has developed the ESMO-Magni-
tude of Clinical Benefit Scale (ESMO-MCBS) 
to evaluate high-quality clinical trial results, 
recognising the need for a standardised 
approach for grading the magnitude of clin-
ical benefit derived from new therapeutic 
approaches.1 The ESMO-MCBS is a reproduc-
ible, semiquantitative tool for grading clinical 
benefit, thereby intending to prioritise ther-
apies that should be rapidly accessible to all 
European citizens. The ESMO-MCBS version 
1.0 is especially designed to evaluate compar-
ative outcome studies in solid cancers.
In ESMO-MCBS v1.0, separate forms were 
developed for the curative and non-curative 
setting—forms 1 and 2. In the non-curative 
setting, a three-step process is implemented 
(figure 1). The strength of the randomised 
evidence is established at the first step, and 
in the second step, based on the quantitative 
component of the scale, a preliminary grade is 
assigned. It incorporates a dual rule that eval-
uates both the observed relative benefit (RB), 
that is, the observed hazard ratio (HR), and 
the observed absolute benefit (AB) on a time-
to-event outcome (progression-free survival 
(PFS) and overall survival (OS)) achieved by 
the treatment. The dual rule consists of the 
following two components:
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Key message
Extensive simulations of plausible trial scenarios 
demonstrate that the ESMO-Magnitude of Clinical 
Benefit Scale (ESMO-MCBS) dual rule, incorporating 
the lower limit of the 95% CI (LL95%CI) threshold 
for HR, addresses both goals of inclusiveness and 
discernment effectively, and more so than a dual rule 
using point estimate (PE) thresholds. The ESMO-MCBS 
avoids excluding a substantial proportion of big benefit 
positive studies from achieving due credit, as would 
be the case if the PE were to be used, and results in 
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Figure 1 The three critical evaluation steps of ESMO-
MCBS.
ESMO, European Society for Medical Oncology; MCBS, Magnitude 
of Clinical Benefit Scale; QoL, quality of life.
Table 1 The ESMO-MCBS dual rule: implemented 
combined thresholds for the HR and the minimum absolute 
benefit (AB) gain for OS and PFS that could be considered 











4 ≤12 months ≤0.65 AND ≥3 months




3 ≤6 months ≤0.65 AND ≥1.5 months
>6 months ≤0.65 AND ≥3 months
*Thresholds refer to the lower limit of the 95% CI.
ESMO, European Society for Medical Oncology; MCBS, Magnitude 
of Clinical Benefit Scale; OS, overall survival; PFS, progression-free 
survival. 
1. RB rule : the lower limit (LL) of the 95% CI for the 
HR is compared with specified threshold values 
(PFS: LL ≤0.65; OS: LL ≤0.65 or LL ≤0.70 for median 
control ≤12 months or >12 months, respectively)
2. AB rule : the observed absolute difference in median 
treatment outcomes is compared with the minimum 
clinically significant AB.
Furthermore, when the primary outcome is OS, the 
preliminary score can also be obtained based on an alter-
native rule evaluating the magnitude of observed long-
term beneficial effect to prespecified threshold values.
In the third step, the grade can be adjusted to reflect 
the toxicity and quality of life (QoL) outcomes of the 
investigative treatment (qualitative component).
The ESMO-MCBS approach to RB evaluation highlights 
the importance of the CI for the HR, which is estimated 
from the observed data and presents a range of values in 
which the true value for HR may lie.2 The RB criterion 
uses the observed HR along with its precision by setting 
a threshold at the LL of the corresponding 95% CI. A 
magnitude of RB included in the interval of HR is a plau-
sible true value for the treatment benefit and should be 
recognised as such. Congruence with meaningful gains 
drives the choice of the LL of the CI of HR (LL95%CI 
rule) as a critical statistic, rather than the point estimate 
(PE rule). The LL95%CI rule is by design more lenient 
for higher true benefit, than the corresponding PE rule, 
minimising the false negative results, that is, maximising 
the sensitivity of the first component of the dual rule.
As a counterbalance, the role of the AB rule is to guarantee 
that the relevant minimum clinically significant AB is observed. 
This required AB gets progressively smaller, the smaller the 
median control time-to-event is (table 1). Thus, the dual 
rule, combining the RB and AB rules, addresses two require-
ments: not penalising treatments that have effects that are 
plausibly congruent with the desired magnitude of RB, while 
penalising treatments that provide only a trivial observed AB.
This approach has been questioned, and concern has 
been expressed that it is excessively lenient especially in 
the setting of lower powered studies while at the same 
time discouraging high powered studies with narrow 95% 
CIs.3–9
To address these concerns, we have carried out exten-
sive simulations to explore the behaviour of the ESMO-
MCBS dual rule using the LL95%CI and compare it with 
the approach using PE within the context of compara-
tive outcome studies. Here we report, for the non-cura-
tive setting, the results of simulations of plausible trial 
scenarios, each replicated 50 000 times.
AIMs
The aims of the current study are:
a. To provide the rationale behind the use of the ESMO-
MCBS dual rule, with emphasis on the use of the 
LL95%CI rule for the assignment of the maximal 
RB and graphically illustrate its behaviour and 
corresponding field testing application
b. To evaluate the sensitivity and specificity of the ESMO-
MCBS LL95%CI rule. To examine the robustness of its 
characteristics for reasonable power (80%–90%) and 
range of targeted and true HRs (range of HRs from 
0.60 to 0.90), and how they compare with RB rules 
based on a range of PE threshold values
c. To evaluate whether the ESMO-MCBS LL95%CI rule 
behaves properly under reasonable design power, by 
not penalising trials that use high power for substantial 
benefit, when true, while penalising trials that use high 
power for small benefit when only small benefit exists
d. To compare sensitivity and specificity of the ESMO-
MCBS v1.0 dual rule to other dual scores based on PE 
rules including those proposed by Sobrero et al10
e. To demonstrate the application of the ESMO MCBS 
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Methods
The behaviour of the ESMO-MCBS v1.0 over the range of 
primary endpoints used in the ESMO-MCBS evaluation 
(either PFS or OS) for the appropriate median control 
range (≤12 or >12 months) and the corresponding design 
power (80%–90%) is illustrated across different design 
HRs. Behaviours were evaluated conceptually and with 
corresponding data from the field testing of ESMO-MCBS 
v1.0.
The ESMO-MCBS Working Group, considered a true 
relative decrease in risk of at least 35% or more (or 30% 
or more, for OS with median control >12 months), as 
deserving the maximal preliminary grade.1 A decrease 
of risk by at least 20% is necessary to satisfy the required 
minimum observed AB chosen by the ESMO-MCBS 
Working Group for achieving the maximal preliminary 
grade when median control for OS or PFS is ≤12 months.1 
An HR of >0.80 is generally considered to correspond to 
a relatively small RB. This convention was endorsed by 
the Working Groups set by the ASCO Cancer Research 
Committee to propose new thresholds for clinically 
meaningful outcomes of cancer medications for meta-
static colon cancer, metastatic breast cancer, non-small 
cell lung cancer and pancreatic cancer. For the cancer 
types examined, the maximum recommended design HR 
for a meaningful clinical trial goal was set at HR=0.80, for 
power 80%–90%.11
The benefit of an experimental treatment is evaluated 
based on the available information, which includes the 
targeted (or design) HR with a specific power according 
to the study design and the observed HR (with corre-
sponding CI). The true HR is not known in real life and 
only through simulations assuming true HR in study 
scenarios one can elicit the behaviour of the different 
evaluation rules.
In the simulations, time-to-event data were produced 
from exponential distributions with parameters selected 
to satisfy the assumptions of the true values for the HR 
and median for the control group. Trial sizes and number 
of events to stop the trial were determined based on 
the design HR and the assumed power. In most of the 
examined scenarios, it was assumed that the trials were 
correctly designed by targeting the true HR (true HR=de-
sign HR). Random censoring was considered throughout 
the simulations. For each combination, 50 000 simulated 
trials were run. For each replication, several characteris-
tics including the observed HR with the corresponding 
95% Wald CI and the observed medians for the control 
and experimental treatment were produced. All calcula-
tions were performed using the R language for statistical 
computing V.3.2.2.12
Three approaches were used to evaluate the performance 
of the ESMO-MCBS LL95%CI threshold for RB. Compar-
ison of the ESMO-MCBS LL95%CI rule with the PE rule for 
a range of threshold values was performed using receiver 
operating characteristic (ROC) curves, plotting true posi-
tive rate against false positive rate across a range of true 
RB levels and study power. Second, through simulations, the 
%acceptance of maximal RB score was used to compare the 
MCBS LL95%CI threshold to the PE thresholds exhibiting 
similar behaviour when the design is correctly targeting the 
true HR, and third, when the design and true HRs differ, 
over a range of true HRs, design HRs and study powers.
Further simulations were run to evaluate the perfor-
mance of the ESMO-MCBS v1.0 dual rules on the per cent 
acceptance of maximal preliminary grade (%acceptance) 
over a range of plausible scenarios. The behaviour of 
dual rules based on the PEs exhibiting a behaviour more 
closely corresponding to the LL95%CI thresholds, as well 
as the ones described by Sobrero et al, was compared with 
the behaviour of the ESMO-MCBS v1.0 dual rules.10
Results
Graphical illustration of the esMo-MCBs v1.0 preliminary 
grading
Assuming trials are correctly designed, the behaviour of 
the ESMO-MCBS LL95%CI rule over the range of design 
HR from 0.60 to 0.90 (targeted HR used in the alter-
native hypothesis) and design power of 80% or 90% is 
presented graphically (figure 2A,B). Each figure reflects 
the MCBS LL95%CI rule for the corresponding median 
control range of the primary endpoint (figure 2A: 
LL95%CI ≤0.65, for PFS, and OS with median control ≤12 
months; figure 2B: LL95%CI ≤ 0.70 for OS with median 
control >12 months; design HR=true HR).
There are several critical observations from this 
illustration:
1. The maximum observed HR leading to a statistically 
significant result (stars in figures) increases as the 
design HR value increases (x-axis). This is the direct 
result of targeting a progressively smaller benefit, 
resulting to a narrower 95% CI centred closer to 1.
2. Trials targeting big benefit (non-shaded area; fig-
ure 2A,B): for significant trials, the LL95%CI rule is 
always satisfied for true HR up to some value (identi-
cal circles and stars) (PFS and OS with median con-
trol ≤12 months, LL95%CI ≤0.65: up to HR ≤0.736 for 
80% power, and HR ≤0.701 for 90% power; OS with 
median control >12 months, LL95%CI ≤0.70: up to 
HR ≤0.77 for 80% power, and HR ≤0.74 for 90% pow-
er).
Thus, a penalty to the ESMO-MCBS v1.0 score for 
such a study will only depend on the magnitude of 
the observed AB, while the RB rule is inactive. It is 
important to emphasise that in this big benefit range 
for true HR, the LL95%CI rule awards maximal RB 
grade to 100% of the significant trials. This translates 
to a bigger number of trials assigned maximal grade 
when designed with 90% power than with 80% power 
(blue circles above red circles).
3. Trials targeting smaller benefit (shaded area: red for 
80% power, blue for 90% power; figure 2A,B): the 
MCBS RB rule assigns the maximal score only for a 
subset of the significant trials. A statistically significant 











pen: first published as 10.1136/esm
oopen-2017-000216 on 9 O
ctober 2017. Downloaded from
 
Open Access
4 Dafni U, et al. ESMO Open 2017;2:e000216. doi:10.1136/esmoopen-2017-000216
Figure 2 Maximum observed HR to achieve statistical significance (two-sided alpha=0.05) and maximum observed HR that 
satisfies the LL95%CI rule for maximal RB, for a range of design HRs . Note: design HR=true HR. (A) OS, median control ≤12 
months; PFS, all medians: LL95%CI ≤0.65. (B) OS: median control >12 months: LL95%CI ≤0.70. 
Annotation: Symbols and shaded area: red for power 80%, blue for power 90%. Stars: maximum observed HR to achieve 
statistical significance (two-sided significance level 0.05). Circles: maximum observed HR that would satisfy the LL95%CI rule 
for maximal RB score for significant trials. Progressively smaller vertical linear segments: corresponding estimated 95% CIs 
(for observed HR). Dotted horizontal lines with median control/gain values listed on the right y-axis: observed HR that would 
correspond to required AB gains and control medians, that is, HR=0.80 broadly corresponds to a 3-month gain for a 12-month 
median control. Non-shaded area in the figures: range for design HR for which stars and circles are identical, representing 
trials targeting relatively big benefit. Shaded area in the figures: range for design HR starting above a certain value, beyond 
which circles are progressively lower than stars, representing trials targeting smaller benefit. 
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Figure 3 Comparison of the LL95%CI rule to a PE threshold for maximal RB classification: sensitivity and specificity for 
the MCBS LL95%CI ≤0.65 rule versus the ROC curve for PE rules ranging from 0.60 to 0.90 (time-to-event median control=6 
months). (A–C) Power 80%. (D–F) Power 90%.
Annotation: Left and centre panels: true HR ≤0.65 and HR≤0.70, are respectively classified as big benefit, contrasted to a 
small benefit classification of true HR>0.80. Right panels: true HR ≤0.75 is classified as a relatively big benefit, contrasted to 
a small benefit classification of true HR>0.75. Red star: the MCBS LL95%CI≤0.65 rule for HR. ROC curve (black): PE rules 
ranging from 0.60 to 0.90.
LL95%CI, lower limit of 95% CI; PE, point estimate; RB, relative benefit; MCBS, Magnitude of Clinical Benefit Scale; ROC, receiver operating 
characteristic.
very close to 1, thus in these large-sized trials, a small 
observed RB can still be statistically significant. When 
large studies target progressively smaller benefits, an 
increasing proportion of trials are penalised by the 
RB rule and consequently the maximum observed HR 
value allowed by the RB rule tends to move further 
away from the maximum observed HR achieving 
significance. This phenomenon is slightly amplified 
with higher power.
simulation results 1: comparison of the ll95%CI and Pe 
thresholds regarding sensitivity and specificity for maximal 
RB grading
Inherent to the choice of any threshold is a contrast 
between false negative and false positive results. The 
best rule would maximise both sensitivity and specificity. 
Assuming that a trial is correctly designed to detect with 
power 80%–90% a true benefit, the ideal rule should 
minimise false-negative results, by not misclassifying an 
experimental treatment as not providing big RB (true HR 
≤0.65, ≤0.70) if in fact it does. This relates to sensitivity. In 
parallel, it should minimise false-positive results, by not 
misclassifying an experimental treatment as providing big 
RB, if in fact it does not (true HR >0.80). This relates to 
specificity.
By these criteria, superiority of the LL95%CI rule over 
a PE rule for the evaluation of RB is demonstrated in 
three tests:
1. ROC curves (figure 3): the optimal result on a ROC 
curve corresponds to the top left corner, that is, 
100% true positive, 0% false positive. The relative 
characteristics of the MCBS rule for maximal RB 
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Figure 4 Comparison of the LL95%CI rule with PE rules with similar behaviour: %acceptance of maximal RB for power 80% 
and 90% over all trials, for LL95%CI ≤0.65 rule, PE <0.75 and PE <0.80.
Note: Initially, for big benefit studies, the %acceptance rate of maximal RB is higher when designed with 90% power versus 
with 80% power. Crossing of 80% and 90% power lines for: LL95%CI ≤0.65 (red lines) occurs at HR=0.73 with %acceptance 
80%; PE <0.75 (green lines) occurs at HR=0.75 with %acceptance 50%; PE <0.80 (blue lines) occurs at HR=0.80 with 
%acceptance 50%.
LL95%CI, lower limit of the 95% CI; PE, point estimate; RB, relative benefit.
compared with a range of PE thresholds and plotted in 
six ROC curves for true HR ranging from 0.60 to 0.90, 
for power 80% and 90% (figure 3). The LL95%CI rule 
(depicted as a red star) compared with a range of PE 
thresholds from 0.60 to 0.90, is almost always above 
and/or to the left of the PE ROC curve, indicating 
optimal balance between maximal true-positive and 
minimal false-positive results.
2. Comparison of the MCBS LL95%CI rule to PE rules 
with similar behaviour: translating the LL95%CI 
rule to similarly behaving PE thresholds, we find that 
LL95%CI ≤0.65 would more closely correspond to the 
behaviour of a PE threshold between 0.75 and 0.80, 
while the LL95%CI ≤0.70 to a PE threshold between 
0.80 and 0.83. Based on %acceptance of maximal RB, 
it is again evident that the LL95%CI rule, for both 
powers 80% and 90%, exhibits consistently higher sen-
sitivity for true big benefit and/or higher specificity 
for true small benefit (figure 4, online supplementary 
figure S1A–C).
In addition, comparing the effect of power on the 
LL95%CI rule, the %acceptance of maximal RB is 
evidently higher among all trials designed with 90% 
power than in studies designed with 80% power, up to 
a relatively big RB (true HR <0.73 for LL95%CI ≤0.65; 
true HR <0.77 for LL95%CI ≤0.70; figure 4, online 
supplementary figure S1B). The same is true for any 
PE rule, but in contrast to the LL95%CI threshold, 
it occurs only up to that specific PE value, at which a 
much lower %acceptance of only 50% is achieved (eg, 
if PE <0.75, then for true HR=0.75, the %acceptance 
among all trials cannot exceed 50%). This disadvan-
tage is even more pronounced when using the lower 
PE threshold values of HR=0.60 or HR=0.65 (see 
online supplementary figure S2A,B).10
3. Sensitivity and specificity for true HR over a range of 
design HRs: the %acceptance of maximal RB grade 
over all trials for the LL95%CI ≤0.65 rule is presented 
for true HR values of 0.65, 0.75 and 0.90 in studies 
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Figure 5 Comparison of the LL95%CI rule to PE rules with similar behaviour, when the true HR is different from the design 
HR: %acceptance of maximal relative benefit, over all trials, for true HR of 0.90, 0.75 and 0.65, over a range of design HRs.
Annotation: Panel headers: true HR (0.65, 0.75  and 0.90) is indicated above design HR (0.65 to 0.90). Height of the bars: 
proportion out of the 50 000 simulated trials satisfying each condition. Grey bars: proportion of simulated trials found 
statistically significant (at two-sided significance level 0.05). Red, green and blue bars: %acceptance using LL95%CI ≤0.65, 
PE of 0.75 and 0.80, respectively. Grey-shaded areas: scenarios with design HR=true HR. Orange-shaded areas: implausible 
scenarios (eg, when true HR=0.65 and design HR≥0.85). 
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The LL95%CI rule presents the desired robust 
behaviour across different targeted HRs for specified 
power.
For true HR=0.90 (top row in figure 5A,B), the 
LL95%CI rule (red bar) has a %acceptance close to 
zero for design HR ≥0.80, similar to PE <0.75 (green 
bar), discouraging the design of large size trials 
targeting small benefit (highest specificity: LL95%CI 
rule and PE <0.75). However, it can be seen that 
small-sized trials targeting relatively big RB (design 
HR ≤0.75) provide a minor but still existing risk to 
reach a false positive conclusion (LL95%CI rule 
similar to PE <0.80 (blue bar)).
On the other end of the spectrum, for true HR=0.65 
(bottom row in figure 5A,B), the LL95%CI ≤0.65 rule 
has %acceptance equal to the corresponding power 
(80% or 90%) for a design HR=0.65, and it increases to 
almost 100% as targeted benefit magnitude decreases 
(highest sensitivity: LL95%CI rule and PE <0.80).
This advantage of the LL95%CI ≤0.65 rule is 
also apparent for true HR=0.75 (middle row in 
figure 5A,B), where the LL95%CI ≤0.65 rule provides 
high %acceptance when big benefit is targeted, 
diminishing %acceptance as targeted benefit gets 
smaller, while it achieves the smallest %acceptance 
for low targeted RB. The PE <0.75 provides %accep-
tance around 50% throughout, while the PE <0.80 
gives higher and higher %acceptance the smaller the 
targeted benefit and the higher the power, thus indi-
cating that the PE <0.75 is insensitive to the design 
HR and power, while the PE <0.80 promotes grossly 
overpowered trials.
In fairness, scenarios of evaluating results from grossly 
overpowered trials (eg, when true HR=0.65 and design 
HR ≥0.80) are not particularly plausible. First, it is not 
reasonable to run an unnecessarily large trial when 
expecting a true big benefit. Second, if such a trial was 
designed based on the initial assumption that the true 
effect is small, the study would probably not continue 
to completion and would stop at the interim analysis, 
which is ethically required in such a large trial.
simulation results 2: comparison of the dual rule based on 
the ll95%CI ≤0.65 or ≤0.70 and on Pe thresholds Pe <0.75, 
Pe <0.80 or Pe <0.83 (thresholds exhibiting similar behaviour).
Assuming that a trial is correctly designed to detect 
with power 80%–90% a true benefit, the %acceptance 
over a range of plausible scenarios for significant trials 
is compared between the dual rule based on the PE 
thresholds behaving similarly to the proposed LL95%CI 
threshold incorporated in ESMO-MCBS v1.0 (figure 6A,B: 
PFS; figure 6C,D: OS; 80% and 90% power).
Big true benefit (illustrated for true HR=0.60, 0.65, 0.70)
In all of these scenarios, the LL95%CI ≤0.65 rule is 
consistently at least as lenient as the PE threshold of 0.80 
(and more lenient than PE <0.75), accepting for highest 
grade almost 100% of the significant trials. The same is 
true for the LL95%CI ≤0.70 rule and the corresponding 
PE <0.80, PE <0.83, respectively, applied when median 
control OS >12 months.
The limiting effect of the strict AB rule, whereby 
maximal preliminary grade is only achieved when AB 
targets are met, is especially pronounced when the OS 
median control is 6 months or less. However, when the 
median OS is long (eg, 24 months), this constraint is lost 
since the AB rule (OS: 5 months gain) is always satisfied.
Smaller true benefit (illustrated for true HR=0.75, 0.80, 0.85)
The PE <0.75 threshold imposes initially a higher penalty, 
which becomes almost identical to the LL95%CI rule 
for true HR >0.80. For true HR=0.75, it overpenalises 
studies compared with the other criteria. When the true 
HR is 0.80 or 0.85, indicating a lower level of benefit, 
the LL95%CI ≤0.65 threshold behaves similarly to the 
PE >0.75 threshold and both are substantially stricter than 
the PE >0.80 threshold.
Thus, over the full range of true HRs, the ESMO-MCBS 
v1.0 dual rule is exhibiting the most desired discrimina-
tory behaviour by being at least as lenient or more than 
the dual rule based on PE <0.80 when the true benefit is 
big, while it is similarly strict to the dual rule based on 
PE <0.75 when true benefit is small (true HR = 0.80, 0.85).
The PE thresholds for the assessment of RB for OS 
that were proposed by Sobrero et al are substantially 
more non-inclusive.10 For example, for median control 
OS of 6 months, this rule leads to a false-negative rate 
of 61% for true HR=0.65, in a correctly designed study 
with power 80% and to 69%, for power 90% (see online 
supplementary figure S3A,B). In the field testing using 
these PE thresholds, two-thirds of the six studies (67%) 
achieving the maximal ESMO-MCBS preliminary grade 
with primary endpoint OS, and judged by the experts 
as deserving it, would have been unduly penalised (see 
online supplementary tables S3 and S4; studies high-
lighted with grey background).
Graphical illustration of the esMo-MCBs v1.0 field testing 
results
The ESMO-MCBS v1.0 preliminary grades of trials evalu-
ated in the field testing are shown along with the relevant 
RB cut-offs over the encountered full range of design HRs 
(figure 7; online supplementary figure S4A–E).1 Each 
figure reflects the primary endpoint used in the ESMO-
MCBS evaluation (either PFS or OS) for the appropriate 
median control range (≤12 or >12 months) and the corre-
sponding design power (80%, or 85%, ≥90%). All symbols, 
lines and shaded areas are as defined before (in figure 2). 
Squares represent actual study information on observed 
HR with corresponding 95% CI (y-axis: observed HR vs 
x-axis: design HR), while their colour indicates whether 
the studies meet the criteria for maximal preliminary 
score (figure 7). The colour of the print in the tabulated 
data from the field testing that is presented in online 
supplementary tables S1–4 corresponds to the colour of 











pen: first published as 10.1136/esm
oopen-2017-000216 on 9 O
ctober 2017. Downloaded from
 
Open Access



























































































































































































































































































































































































































































































pen: first published as 10.1136/esm
oopen-2017-000216 on 9 O
ctober 2017. Downloaded from
 
Open Access
10 Dafni U, et al. ESMO Open 2017;2:e000216. doi:10.1136/esmoopen-2017-000216
Figure 7 Field testing results relative to the maximal preliminary grade and maximum observed HR (95% CI) for primary 
outcome PFS—study power 80%. 
Annotation: Squares: actual study information (y-axis: study observed HR and 95%CI; x-axis: study design HR); Green 
squares: study meeting both maximal RB & AB criteria; Blue squares: study meeting maximal RB but not AB criteria; Red 
squares: study meeting neither criterion; Other symbols, lines and shaded areas as in Fig. 2.
PFS, progression-free survival; RB, relative benefit; AB, absolute benefit; UL, upper limit; LL, lower limit.
As an example, 10 trials evaluated by the ESMO-MCBS 
v1.0, with PFS and median control ≤12 months targeting a 
design HR ranging from 0.54 to 0.80 with power 80%, are 
shown in figure 7. Among them, six satisfied both the RB 
and AB criteria for maximal preliminary grade, while four 
satisfied the RB criterion but not the AB (figure 7- online 
supplementary table S1).
Information is presented for 54 superiority trials involving 
nine tumour types in non-curative disease with adequate 
information on the study design (see online supplemen-
tary tables S1–4). Of note, all trials are targeting HR up to 
0.80, with the exception of one trial (PREVAIL) that targets 
HR=0.83 with primary endpoint OS and median control 
survival above 12 months and, in fact, this study stopped 
at the interim analysis with HR=0.71 (95% CI 0.60 to 0.84) 
(see online supplementary figure S4C and table S3).
Overall, the balance between the RB and the AB rule, 
the first being more lenient and the latter generally 
stricter, appears to provide for a fair ESMO-MCBS grade 
assignment to the experimental treatments, as shown 
both through simulations and in the field testing results.
dIsCussIon
Credibility and validity are critically important for 
the development and value of the ESMO-MCBS, and 
ESMO has emphasised its compliance with standards for 
‘accountability for reasonableness’ in the development 
process of the scale.13 14 The validity of the ESMO-MCBS 
is derived from: (1) clinically relevant and reasonable 
criteria for prioritisation of different types of benefit, that 
is, that cure takes precedence over deferral of death, that 
direct endpoints such as OS and QoL take precedence 
over less reliable surrogates such as PFS or RR and that 
the interpretation of the evidence for benefit derived 
from indirect primary outcomes (such as PFS or RR) may 
be influenced by secondary outcome data; (2) coher-
ence: procedural agreements regarding the evidence to 
be used/not used, how it will be analysed and evaluated 
and precautions to minimising bias (including conflict of 
interest issues) based on an understanding of the rela-
tive strengths and weaknesses of the usual measured 
outcomes OS and QoL, and their surrogates, as well as 
rigorous biostatistical review; (3) wide applicability over a 
range of solid cancers and a range of prognoses that have 
been rigorously tested; (4) statistical validity; and (5) a 
transparent process of development with scope for peer 
review, appeal and revision.1
Commitments to transparency and statistical validity 
underscore this unprecedented detailing of the statistical 
deliberations essential to the structure and workings of 
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The ESMO-MCBS aimed to have characteristics of inclu-
siveness and discernment. Inclusiveness refers to the quality 
that if a trial has adequate power and targets a clinically 
meaningful RB, then if found significant, the experimental 
treatment should not be penalised unfairly. Discernment, in 
contrast, refers to the ability to identify the situation where, 
if a trial is unjustifiably large and has adequate power for a 
small benefit gain that is less than the clinically meaningful 
benefit, then if found significant, the experimental treat-
ment should be somehow penalised.
The choice of the LL95%CI as a threshold for assigning 
the MCBS score, first and foremost, serves the purpose 
of taking into account the variability of the estimate. The 
alternative of using the PE fails in that regard. The use 
of the LL95%CI for threshold evaluation has been the 
source of confusion, consternation and scepticism, with 
the often stated concern that it would increase the like-
lihood of small benefit studies being overcredited with 
greater benefit than is justifiable.3–9 The data generated 
by the extensive simulations and field testing presented in 
this paper are reassuring, and they indicate that the use 
of the LL95%CI approach gives the best balance of mini-
mising false-negative results (inclusivity) and minimising 
false-positive results (discernment) in the identification 
of studies reaching thresholds for maximal grade in the 
preliminary scoring of the ESMO-MCBS v1.0. In addition, 
the use of the LL95%CI demonstrates desired discrimina-
tory behaviour for different powers, true HR values and 
different design HRs better than PE approaches.
When comparing the ESMO-MCBS scoring approach 
to an approach with PE thresholds exhibiting the closest 
behaviour to the chosen MCBS LL95%CI cut-off values 
(PE <0.75, 0.80 or 0.83), it was again demonstrated that for 
a range of true HRs, the MCBS rule was overall more sensi-
tive and more specific. This advantage held whether the 
design was adequately applied for the true benefit (design 
HR=true HR), or not. In addition, this advantage was much 
more pronounced, when lower cut-off values, such as those 
proposed by Sobrero et al (HR=0.60, 0.65), were used.10
Finally, the concern that by taking into account the 
variability of the estimate, the LL95%CI threshold would 
penalise larger studies and promote smaller ones, was 
shown not to hold. In fact, the LL95%CI rule had a higher 
%acceptance for reasonable benefit trials, when designed 
with 90% power than when designed with 80% power. 
For smaller true benefit, this is reversed (ie, achieving 
a higher %acceptance for studies designed with 80% vs 
90% power). Using the LL95%CI threshold, this reversal 
occurs at true HRs <0.73, or 0.77 for LL95%CI ≤0.65 and 
≤0.70, respectively, and at an acceptance rate of approxi-
mately 80% for maximal benefit grade. When using a PE 
threshold, this reversal occurs at that PE threshold value 
and at an acceptance rate limited to 50% for maximal 
grading. Of note, this means that for trials evaluated 
based on the previously advocated PE cut-offs of 0.60 or 
0.65, this reversal is present for much bigger RB values, 
which is a non-desirable property.10
Together these simulations demonstrate that the 
MCBS dual rule incorporating the LL95%CI threshold 
for HR addresses both goals of inclusiveness and 
discernment more effectively than a dual rule using 
PE thresholds. Inclusiveness: RB assessment using the 
LL95%CI for HR rather than a PE threshold avoids 
excluding a substantial proportion of big benefit 
positive studies from achieving due credit as would 
be the case if the PE were to be used. Discernment: 
the combined RB using the LL95%CI and AB assess-
ment results in downgrading more trials with a statis-
tically significant but clinically insignificant observed 
benefit. The stricter behaviour occurs earlier when 
power is 90% vs 80%, and this is in fact the desired 
behaviour. It results in not assigning maximal prelim-
inary grade to more trials found significant based on 
a relatively small observed benefit (HR close to the 
null) due to a large sample size.
The dual rule incorporating both AB and RB is not 
unique to the ESMO-MCBS; it is also used in the approach 
advocated by Sobrero et al.10 Among the magnitude of 
clinical benefit and value scales published thus far, only 
the ESMO-MCBS uses the LL95%CI rather than PE for 
evaluation of RB.10 15–17
A limitation of the exploration of the ESMO-MCBS 
v1.0 through both the field testing and the simulations 
reported here is that it is performed only for trials that 
make available the relevant design characteristics, that 
is, power and targeted RB, by including them in the 
published trial report.
Since the ESMO-MCBS aims to provide a structured, 
valid, reasonable and reproducible approach for data inter-
pretation, the findings of this statistical exploration have 
implications for data interpretation in general while it 
promotes the importance of reporting HR CIs.2 18
Two important lessons were derived from these 
statistical explorations that will be salient for future 
revision of the ESMO-MCBS. The simulations identi-
fied a shortcoming in v1.0 such that when the control 
OS is greater than 24 months, there was no AB 
constraint on RB scoring. Second, it was shown that 
small-sized trials provide a relatively small but still 
existing risk to reach a false-positive conclusion. Both 
of these issues will be addressed in v1.1: the former 
with the introduction of a new prognostic subgroup 
for OS studies where the median OS of the control 
arm is >24 months; the latter with the specific iden-
tification of small randomized phase II studies and 
a disclaimer recommending that confirmation of the 
beneficial outcome based on larger trials is warranted.
Future research will evaluate the factors contrib-
uting to divergent grading outcomes when using the 
ESMO-MCBS and the ASCO Value Framework and 
the relative characteristics of threshold evaluation 
using LL95%CI as compared with the approach to 
RB evaluation of the German Institute for Quality 
and Efficiency in Health Care, which uses UL95%CI 
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in the grading system of the ESMO-MCBS are those 
prescribed in the CONSORT statements.21 22 These 
standards are likely to evolve and, if so, ESMO-MCBS 
will be revised to remain constant with contempo-
raneous standards for reporting. Novel statistical 
approaches such as restrictive mean survival time 
have not yet gained CONSORT endorsement and are 
not widely reported.23 Should they be incorporated 
into reporting standards, they will also be incorpo-
rated into future versions of the ESMO-MCBS.
ConClusIon
This study illustrates the statistical rationale of the evalu-
ation of RB thresholds using the LL95%CI in preference 
to a PE threshold. The simulations demonstrate that no 
set of rules can accommodate every possible situation and 
that the aims of scale development are to identify the best 
balance between incisiveness and discrimination while 
acknowledging that no approach will be perfect. The 
ESMO-MCBS is an evolving tool with underlying rules 
that will be regularly improved and adapted according 
to the results of repeated rigorous testing and feedback 
from users and stakeholders.
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